vs

Side-by-side financial comparison of P10, Inc. (PX) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $81.0M, roughly 1.6× P10, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -4.7%). P10, Inc. produced more free cash flow last quarter ($18.1M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 10.7%).

P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

PX vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.6× larger
ZLAB
$127.1M
$81.0M
PX
Growing faster (revenue YoY)
ZLAB
ZLAB
+21.8% gap
ZLAB
17.1%
-4.7%
PX
More free cash flow
PX
PX
$44.8M more FCF
PX
$18.1M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
10.7%
PX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PX
PX
ZLAB
ZLAB
Revenue
$81.0M
$127.1M
Net Profit
$9.5M
Gross Margin
51.0%
Operating Margin
31.9%
-54.6%
Net Margin
11.7%
Revenue YoY
-4.7%
17.1%
Net Profit YoY
79.0%
EPS (diluted)
$0.08
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PX
PX
ZLAB
ZLAB
Q4 25
$81.0M
$127.1M
Q3 25
$75.9M
$115.4M
Q2 25
$72.7M
$109.1M
Q1 25
$67.7M
$105.7M
Q4 24
$85.0M
$108.5M
Q3 24
$74.2M
$101.8M
Q2 24
$71.1M
$100.1M
Q1 24
$66.1M
$87.1M
Net Profit
PX
PX
ZLAB
ZLAB
Q4 25
$9.5M
Q3 25
$2.1M
$-36.0M
Q2 25
$3.4M
$-40.7M
Q1 25
$4.5M
$-48.4M
Q4 24
$5.3M
Q3 24
$1.4M
$-41.7M
Q2 24
$7.0M
$-80.3M
Q1 24
$5.0M
$-53.5M
Gross Margin
PX
PX
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
PX
PX
ZLAB
ZLAB
Q4 25
31.9%
-54.6%
Q3 25
14.1%
-42.3%
Q2 25
24.4%
-50.3%
Q1 25
16.6%
-53.3%
Q4 24
26.9%
-62.6%
Q3 24
11.9%
-66.6%
Q2 24
23.7%
-76.0%
Q1 24
18.3%
-80.7%
Net Margin
PX
PX
ZLAB
ZLAB
Q4 25
11.7%
Q3 25
2.8%
-31.2%
Q2 25
4.7%
-37.3%
Q1 25
6.7%
-45.8%
Q4 24
6.2%
Q3 24
1.9%
-40.9%
Q2 24
9.8%
-80.2%
Q1 24
7.6%
-61.4%
EPS (diluted)
PX
PX
ZLAB
ZLAB
Q4 25
$0.08
$-0.05
Q3 25
$0.02
$-0.03
Q2 25
$0.03
$-0.04
Q1 25
$0.04
$-0.04
Q4 24
$0.05
$-0.09
Q3 24
$0.01
$-0.04
Q2 24
$0.06
$-0.08
Q1 24
$0.04
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PX
PX
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$28.2M
$689.6M
Total DebtLower is stronger
$373.2M
Stockholders' EquityBook value
$403.5M
$715.5M
Total Assets
$928.3M
$1.2B
Debt / EquityLower = less leverage
0.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PX
PX
ZLAB
ZLAB
Q4 25
$28.2M
$689.6M
Q3 25
$40.0M
$717.2M
Q2 25
$33.4M
$732.2M
Q1 25
$74.4M
$757.3M
Q4 24
$67.5M
$779.7M
Q3 24
$61.5M
$616.1M
Q2 24
$31.2M
$630.0M
Q1 24
$29.0M
$650.8M
Total Debt
PX
PX
ZLAB
ZLAB
Q4 25
$373.2M
Q3 25
$393.4M
Q2 25
$373.0M
Q1 25
$357.2M
Q4 24
$319.8M
Q3 24
$319.4M
Q2 24
$300.6M
Q1 24
$314.0M
Stockholders' Equity
PX
PX
ZLAB
ZLAB
Q4 25
$403.5M
$715.5M
Q3 25
$396.8M
$759.9M
Q2 25
$388.9M
$791.7M
Q1 25
$374.3M
$810.8M
Q4 24
$386.9M
$840.9M
Q3 24
$394.1M
$667.7M
Q2 24
$396.9M
$704.2M
Q1 24
$400.1M
$762.2M
Total Assets
PX
PX
ZLAB
ZLAB
Q4 25
$928.3M
$1.2B
Q3 25
$936.0M
$1.2B
Q2 25
$932.2M
$1.2B
Q1 25
$877.4M
$1.2B
Q4 24
$869.3M
$1.2B
Q3 24
$857.0M
$985.3M
Q2 24
$823.2M
$987.4M
Q1 24
$832.8M
$988.4M
Debt / Equity
PX
PX
ZLAB
ZLAB
Q4 25
0.93×
Q3 25
0.99×
Q2 25
0.96×
Q1 25
0.95×
Q4 24
0.83×
Q3 24
0.81×
Q2 24
0.76×
Q1 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PX
PX
ZLAB
ZLAB
Operating Cash FlowLast quarter
$23.0M
$-26.0M
Free Cash FlowOCF − Capex
$18.1M
$-26.7M
FCF MarginFCF / Revenue
22.3%
-21.0%
Capex IntensityCapex / Revenue
6.0%
0.5%
Cash ConversionOCF / Net Profit
2.43×
TTM Free Cash FlowTrailing 4 quarters
$14.1M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PX
PX
ZLAB
ZLAB
Q4 25
$23.0M
$-26.0M
Q3 25
$-8.6M
$-32.0M
Q2 25
$13.4M
$-31.0M
Q1 25
$-4.7M
$-61.7M
Q4 24
$101.0M
$-55.8M
Q3 24
$27.5M
$-26.8M
Q2 24
$34.8M
$-42.2M
Q1 24
$11.0M
$-90.1M
Free Cash Flow
PX
PX
ZLAB
ZLAB
Q4 25
$18.1M
$-26.7M
Q3 25
$-9.5M
$-35.0M
Q2 25
$11.6M
$-33.9M
Q1 25
$-6.0M
$-63.2M
Q4 24
$96.6M
$-58.4M
Q3 24
$25.2M
$-28.2M
Q2 24
$33.9M
$-42.9M
Q1 24
$10.7M
$-91.1M
FCF Margin
PX
PX
ZLAB
ZLAB
Q4 25
22.3%
-21.0%
Q3 25
-12.6%
-30.4%
Q2 25
15.9%
-31.1%
Q1 25
-8.9%
-59.9%
Q4 24
113.6%
-53.8%
Q3 24
34.0%
-27.7%
Q2 24
47.7%
-42.9%
Q1 24
16.2%
-104.5%
Capex Intensity
PX
PX
ZLAB
ZLAB
Q4 25
6.0%
0.5%
Q3 25
1.2%
2.6%
Q2 25
2.5%
2.6%
Q1 25
1.9%
1.5%
Q4 24
5.2%
2.4%
Q3 24
3.0%
1.3%
Q2 24
1.3%
0.7%
Q1 24
0.4%
1.1%
Cash Conversion
PX
PX
ZLAB
ZLAB
Q4 25
2.43×
Q3 25
-4.01×
Q2 25
3.96×
Q1 25
-1.05×
Q4 24
19.12×
Q3 24
19.54×
Q2 24
4.98×
Q1 24
2.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PX
PX

Management Fees$78.1M96%
Advisory Fees$1.8M2%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons